Genetic Strategies for Identifying New Drug Targets

作者: Andrej Trauner , Christopher M. Sassetti , Eric J. Rubin

DOI: 10.1128/MICROBIOLSPEC.MGM2-0030-2013

关键词:

摘要: Genetic strategies have yet to come into their own as tools for antibiotic development. While holding a lot of initial promise, they only recently started bear fruit in the quest new drug targets. An ever-increasing body knowledge is showing that genetics can lead significant improvements success and efficiency discovery. Techniques such high-frequency transposon mutagenesis expression modulation matured been applied successfully not identification characterization targets, but also validation tractable weaknesses bacteria. Past experience shows choosing targets must rely on gene essentiality alone, rather needs incorporate system whole. The ability manipulate genes key ensuring we understand entire set processes are affected by treatment. Focusing exacerbating these perturbations, together with which resistance has occurred—both enabled genetic approaches—may point us toward successful development combination therapies engineered based underlying biology.

参考文章(131)
Ying Zhang, D. Mitchison, The curious characteristics of pyrazinamide: a review. International Journal of Tuberculosis and Lung Disease. ,vol. 7, pp. 6- 21 ,(2003)
D. A. Mitchison, Role of individual drugs in the chemotherapy of tuberculosis. International Journal of Tuberculosis and Lung Disease. ,vol. 4, pp. 796- 806 ,(2000)
Nicholas Judson, John J. Mekalanos, TnAraOut, A transposon-based approach to identify and characterize essential bacterial genes Nature Biotechnology. ,vol. 18, pp. 740- 745 ,(2000) , 10.1038/77305
C Kendall Stover, Paul Warrener, Donald R VanDevanter, David R Sherman, Taraq M Arain, Michael H Langhorne, Scott W Anderson, J Andrew Towell, Ying Yuan, David N McMurray, Barry N Kreiswirth, Clifton E Barry, William R Baker, None, A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. ,vol. 405, pp. 962- 966 ,(2000) , 10.1038/35016103
Jyothi Rengarajan, Christopher M. Sassetti, Vera Naroditskaya, Alexander Sloutsky, Barry R. Bloom, Eric J. Rubin, The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Molecular Microbiology. ,vol. 53, pp. 275- 282 ,(2004) , 10.1111/J.1365-2958.2004.04120.X
J. Rengarajan, B. R. Bloom, E. J. Rubin, Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 8327- 8332 ,(2005) , 10.1073/PNAS.0503272102
John D. McKinney, Kerstin Höner zu Bentrup, Ernesto J. Muñoz-Elías, Andras Miczak, Bing Chen, Wai-Tsing Chan, Dana Swenson, James C. Sacchettini, William R. Jacobs, David G. Russell, Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase Nature. ,vol. 406, pp. 735- 738 ,(2000) , 10.1038/35021074
Giovanna Poce, Robert H. Bates, Salvatore Alfonso, Martina Cocozza, Giulio Cesare Porretta, Lluís Ballell, Joaquin Rullas, Fátima Ortega, Alessandro De Logu, Emanuela Agus, Valentina La Rosa, Maria Rosalia Pasca, Edda De Rossi, Baojie Wae, Scott G. Franzblau, Fabrizio Manetti, Maurizio Botta, Mariangela Biava, Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLOS ONE. ,vol. 8, ,(2013) , 10.1371/JOURNAL.PONE.0056980
David J. Payne, Michael N. Gwynn, David J. Holmes, David L. Pompliano, Drugs for bad bugs: confronting the challenges of antibacterial discovery Nature Reviews Drug Discovery. ,vol. 6, pp. 29- 40 ,(2007) , 10.1038/NRD2201
Omar H Vandal, Lynda M Pierini, Dirk Schnappinger, Carl F Nathan, Sabine Ehrt, A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis Nature Medicine. ,vol. 14, pp. 849- 854 ,(2008) , 10.1038/NM.1795